Supplemental Table 1. **Oligonucleotides used in this study.**

Plasmid[a]	Description[b]	Oligo name	Sequence (5'-3')[c]
pPH158	*mrpC* for	oPH485	catggatccCacggtttcaaccgccccctc
	mrpC rev	oPH486	ggctcgagctacttctccttgccggcgatc
pPH165	*ΔmazF* A	oPH518	cggaattcaagagcgtctcggggtgc
	ΔmazF B	oPH519	**ctggaagcg**accgcggttgattcgctcg
	ΔmazF C	oPH520	**aaccgcggt**cgcttccagcaggtgtcg
	ΔmazF D	oPH521	gcggatccCgcagggtcaagacgagc
pPH165	*ΔmrpC* A	oPH487	gcggaattcCacctccgcccaccacac
	ΔmrpC B	oPH488	**gatacggcc**ggaaccgatggggccgag
	ΔmrpC C	oPH489	**atcggttcc**ggccgtatcctctgcgtg
	ΔmrpC D	oPH490	gcgggatccatgagccgctcgcggagc

[a] Primers used for each plasmid construction are listed.
[b] Primers labeled as A, B, C, or D represent the primers used for the two-step PCR fragment fusion process [described in (1)]. Primers are otherwise labeled as forward (for) or reverse (rev).
[c] Bolded sequences indicate the overlapping regions used to combine PCR fragments. Underlined sequences indicate restriction sites used for cloning.

1. Lee, B., Schramm, A., Jagadeesan, S., and Higgs, P. I. (2010) *Methods Enzymol* **471**, 253-278